You are here:

Forthcoming Submission: afamelanotide (Scenesse)

Indication: for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP). Scenesse is to be administered under a Post-Authorisation Safety Study (PASS) protocol in line with the approved European Medicines Agency Risk Management Plan.

Drug Details

Drug Name: afamelanotide (Scenesse)
Drug Manufacturer: Clinuvel (UK) Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
1/05/2017
SMC Meeting Date: 4/07/2017
Advice Due: To be confirmed

Back